Skip to main content
S&P 5007,676.77+0.70%DOW52,361.58+0.28%NASDAQ26,169.38+0.82%BTC$80,129.00+0.25%ETH$2,324.65+0.23%GOLD$4,027.20-0.28%OIL$101.22-0.53%
Smart Investors Daily
SID Premium
MC

NASDAQ · MCRB

Seres Therapeutics, Inc.

Healthcare · Biotechnology

$1.98

Down-$0.11 (-5.26%)

Updated Oct 27, 2026, 4:54 AM

SID Score

2.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
151.06M
P/E ratio
27.95
Dividend yield
0.00%
52-week range
$2.00 – $29.98
Volume
53.07K
Avg. volume
192.86K

Price performance · MCRB

MCRB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

MCRB closed at $1.98 after 21 trading sessions, down 43.75% for the selected period.

Last close
$1.98
Period change
-43.75%
Period low
$1.98
Period high
$3.52
Daily close
View OHLC price history
MCRB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$2.11$2.185$1.98$1.9853.07K
Oct 23, 2026$2.13$2.17$2.00$2.0969.71K
Oct 22, 2026$2.29$2.30$2.02$2.13132.2K
Oct 21, 2026$2.30$2.40$2.2609$2.3041.77K
Oct 20, 2026$2.41$2.5499$2.31$2.3166.98K
Oct 19, 2026$2.46$2.58$2.415$2.4223.37K
Oct 16, 2026$2.56$2.56$2.422$2.4638.57K
Oct 15, 2026$2.40$2.6099$2.40$2.5324.61K
Oct 14, 2026$2.65$2.66$2.385$2.4242.97K
Oct 13, 2026$2.66$2.66$2.51$2.5344.06K
Oct 12, 2026$2.75$2.78$2.66$2.6854.28K
Oct 9, 2026$2.65$2.75$2.58$2.7179.41K
Oct 8, 2026$2.68$2.7243$2.42$2.63213.36K
Oct 7, 2026$2.86$3.00$2.70$2.7260.38K
Oct 6, 2026$2.875$3.0198$2.80$2.9076.42K
Oct 5, 2026$2.91$2.91$2.81$2.8563.3K
Oct 2, 2026$2.98$3.20$2.91$2.94100.95K
Oct 1, 2026$3.10$3.41$2.83$2.93247.33K
Sep 30, 2026$3.4733$3.4855$3.26$3.3554.61K
Sep 29, 2026$3.54$3.585$3.35$3.4871.29K
Sep 28, 2026$3.49$3.55$3.4051$3.5255.49K

Latest MCRB news

The latest Smart Investors Daily articles mentioning MCRB.

Stock researchCompany · Overview

MCRB research

Overview

Company profile and research snapshot.

Company profile

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.25
Implied upside
—
Analysts
—
MCRB recent ratings
DateFirmRatingTarget
Jun 23, 2026HC Wainwright & Co.Buy—
Mar 13, 2026Canaccord GenuityBuy—
Sep 24, 2025Canaccord GenuityBuy—
May 8, 2025Chardan CapitalNeutral—
Mar 20, 2025Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 15, 2026

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube SER-428 significantly reduced gastrointestinal abundance of clinically relevant pathogens in preclinical in vivo colonization models CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that preclinical data supporting the development o

Yahoo · Sep 8, 2026

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4, 2026, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 4,200 shares of its common stock to two new employees. These stock options are subject to the terms of the Seres Therapeutics, Inc. 2022 Emp

Yahoo · Sep 7, 2026

Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences

Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics Market by Type of Product, Route of Administration, Target Indication, Therapeutic Area, End User and Geographical Regions - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global microbiome therapeutics market is projected to increase from USD 0.6 billion in 2026 to USD 4.6 billion by 2035, registering a compound annual growth rate of 25.4% during the forecast period. Market expansion

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By